Boston Scientific Peripheral Interventions’ Post

Important milestone for our company as we announced early completion of enrollment in LunAIRo, Apnimed’s Phase 3 #OSA #clinicaltrial examining the efficacy and safety of AD109 compared to placebo at six-months and one-year. We believe AD109 has the potential to be the first nighttime oral pharmacologic treatment for people with obstructive #sleepapnea who are either intolerant of, or refuse to use, positive airway pressure therapy. We want to thank the patients who volunteered to participate in this study, extend our gratitude to the investigators for their support and give a shout out to our amazing clinical and medical colleagues who made this important step possible. Topline data expected mid-2025. Learn more about the study design and its presentation at #ATS2024: https://bit.ly/4draxhP #biotech #innovation

🎉 We are thrilled to announce Dr. Deborah Jones, Ph.D, EMEIA Sales Director at Proveris Scientific Corporation, is an Official Speaking Partner at the 5th Annual Inhalation and Respiratory Drug Delivery Conference in Berlin, Germany, from September 18-20, 2024. 📍 Join Deborah at Eurostars Berlin Luxury Class Hotel for insightful discussions on inhalation and nasal drug delivery testing solutions. PRESENTATION OVERVIEW Derisking OINDP Development: Incorporating nasal sprays, PMDIs, SMIs, and DPIs 🔹Understand the multifaceted interactions between patient, formulation, and device in OINDP development. 🔹Explore the unique development challenges of each drug type. 🔹Learn how to utilize knowledge and tools to gain insights and mitigate risks in product development. 📨 Connect in advance of the conference: djones@proveris.com 🌐 Visit the conference website: https://lnkd.in/dkTgGQFU #Proveris #Instruments #LaboratoryTestServices #OINDP #InhalerTesting #NasalSprayTesting #DrugDevelopment

Get to know the benefits of these partnerships, with insights and examples from NIH and Curia experts who have been involved for years. Key Objectives: How programs maximize collaboration and support Pairing deep expertise with unparalleled technology access How investment can unlock otherwise-missed potential https://lnkd.in/gnuMP2rs #WhatWeDoMatters #FromCuriositytoCure Curia

Caporali, et al. present their results of their analysis of four Phase 3 trials to show the long-term efficacy and safety profile of baricitinib. They found that baricitinib was efficacious and safe for the long-term treatment of RA. You can find the full paper summary on the IMID Forum completely free along with the latest updates in #RhematoidArthritis 📈 🔗 https://lnkd.in/e24RiNRp

In drug discovery, many promising treatments get stuck in the "valley of death," the gap between candidate compounds and clinical implementation. Discover how Curia and the US National Institutes of Health (NIH) are transforming this landscape by uniting government, industry, and academic resources to overcome these obstacles. Explore C&EN’s white paper to gain insights from Curia and NIH experts: https://ow.ly/futx50SMyFh ------ Explore Curia’s strategic partnerships to advance drug research. Contact us: https://ow.ly/mXkv50SJcqK #DrugDiscovery #CDMO #PharmaInnovation #ClinicalResearch

Attending #ATS2024? Don’t miss Monday’s poster presentation examining the rationale and design of Apnimed’s Phase 3 #clinicaltrial, LunAIRo. LunAIRo examines the efficacy and safety of AD109 compared to placebo at six-months and one-year in a range of obstructive #sleepapnea patients across all types of #OSA from mild to severe and ranges of body mass index from healthy to obese. We believe AD109 has the potential to be the first nighttime oral pharmacologic treatment for people with OSA. More details on LunAIRo and the presentation at: https://t.co/eodrJwnb5M #biotech #innovation

Get familiarized with the new designations being ascribed to the drugs now and then only at PharmaShots!  PharmaShots brings every month a Designation report, highlighting the designations allotted to drugs in various geographies. This month, we have covered designations from the US, China, and EU regions. For a curated report on the designation of your need, reach out to us at connect@pharmashots.com Stay Tuned for more updates! #usfda #ema #us #eu #orphandrugdesignation #fasttrackdesignation #breakthroughtherapydesignation #breakthroughdevicedesignation #regenerativemedicineadvancedtherapydesignation #rarepediatricdiseasedesignation #priorityreview #designations #regulatory #nmpa #china

The identification and management of patients at high bleeding risk (HBR) undergoing TAVI are of major importance, but the lack of standardised definitions is challenging for trial design, data interpretation, and clinical decision-making. The Valve Academic Research Consortium for High Bleeding Risk (VARC-HBR) is a collaboration among leading research organisations, regulatory authorities, and physician-scientists from Europe, the USA, and Asia, with a major focus on TAVI-related bleeding. This document represents the first pragmatic approach to a consistent definition of HBR evaluating the safety and effectiveness of procedures, devices and drug regimens for patients undergoing TAVI. Philippe GAROT https://ow.ly/mYNi50S3PKh

For testing a new drug, a statistician plays a crucial role in clinical trials phases 1 to 3. In our TT4CL project Professor Neal Alexander from LSHTM was responsible for this important task … Read more … #DrugDevelopmentResearch #LSHTM #TT4CL #HaDEAagency #EUfunded #EU4Health #EUHealthUnion #InfectiousSkinDiseases

In a recent interview with Drug Development & Delivery, Chief Commercial Officer of Resilience, Syed T. Husain, shared how Resilience is bringing forward thinking to disrupt the biomanufacturing landscape to increase access to medicines. Read the full article to learn why Resilience was built from a need to revolutionize the CDMO space: https://hubs.ly/Q02kT6qW0